Heska Shares Outstanding 2006-2021 | HSKA

Heska shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Heska Annual Shares Outstanding
(Millions of Shares)
2020 9
2019 7
2018 8
2017 8
2016 7
2015 7
2014 6
2013 6
2012 5
2011 5
2010 5
2009 5
2008 5
2007 6
2006 5
2005 5
Heska Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 10
2021-03-31 10
2020-12-31 9
2020-09-30 9
2020-06-30 9
2020-03-31 8
2019-12-31 7
2019-09-30 8
2019-06-30 7
2019-03-31 8
2018-12-31 8
2018-09-30 7
2018-06-30 8
2018-03-31 8
2017-12-31 8
2017-09-30 8
2017-06-30 8
2017-03-31 8
2016-12-31 7
2016-09-30 7
2016-06-30 7
2016-03-31 7
2015-12-31 7
2015-09-30 7
2015-06-30 7
2015-03-31 7
2014-12-31 6
2014-09-30 7
2014-06-30 6
2014-03-31 6
2013-12-31 6
2013-09-30 6
2013-06-30 6
2013-03-31 6
2012-12-31 5
2012-09-30 5
2012-06-30 6
2012-03-31 5
2011-12-31 5
2011-09-30 5
2011-06-30 5
2011-03-31 5
2010-12-31 5
2010-09-30 5
2010-06-30 5
2010-03-31 5
2009-12-31 5
2009-09-30 5
2009-06-30 5
2009-03-31 5
2008-12-31 5
2008-09-30 5
2008-06-30 5
2008-03-31 5
2007-12-31 6
2007-09-30 6
2007-06-30 6
2007-03-31 5
2006-12-31 5
2006-09-30 5
2006-06-30 5
2006-03-31 5
2005-12-31 5
2005-09-30 5
2005-06-30 5
2005-03-31 5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.744B $0.197B
Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29